

The logo for BIO CHINA, featuring a stylized blue and black wave or ribbon design.

BIO CHINA | 2026 Fusion Forward

International Convention

March 12-14, 2026 Suzhou International Expo Center

✉ BIOCHINA@enmore.com


About BIOCHINA

BIOCHINA 2026 (11th) will be held from **March 12-14** at the Suzhou International Expo Center. Following the success of BIOCHINA 2025 (10th), which welcomed **30,000 attendees** in Suzhou, BIOCHINA continues its journey of boundless innovation and collaborative growth!

Over the past decade, BIOCHINA has **expanded from China's thriving biopharmaceutical sector to the world stage**, establishing an international platform for industry connectivity and uniting global expertise to advance collaboration.

Through technological breakthroughs, commercial implementation, capital support, and ecosystem integration, BIOCHINA has witnessed China's innovative drug industry evolve from following to leading, progressing alongside the industry and the times.

BIOCHINA2026 Fusion & Forward
 'Fusion' embodies the power of an ecosystem, where diverse forces converge to unlock growth. 'Forward' represents future direction, pushing boundaries to define new heights for the industry. Standing at the threshold of a new decade, BIOCHINA 2026 will join hands with global partners to step into the next golden era of China's biopharmaceutical industry.



- 30000+** Attendees
- 400+** Exhibitors
- 850+** Speakers
- 40+** Countries

About the Conference

As a flagship event in China's biopharmaceutical industry, BIOCHINA is dedicated to promoting innovation and industrial translation in the sector. Centered on innovative drugs, the conference provides a comprehensive industry platform connecting research achievements, clinical needs, industrial application, and business development, fostering the exchange of cutting-edge technologies and best practices in industrialization.

In BIOCHINA 2025, the conference invited **74** chairs, Expert Committee Members, and Conference Producers and **850** speakers, creating **204** forums, **12** closed-door meetings, **25** brainstorming sessions, and initiating **10,000+** one-on-one BiOPartnering meetings.

BIOCHINA 2026 will continue to enhance both content and organization, **launching 20 inaugural forums. With industry tracks as the core focus, the conference will delve into specialized technologies, promote upstream and downstream industry collaboration, and bring together global experiences, driving efficient development of innovative drugs worldwide.**



BIOCHINA 2026 (11th Edition) Agenda

	Time	Meeting Room1	Meeting Room2	Meeting Room3	Meeting Room4	Meeting Room5	Meeting Room6	Meeting Room7	Meeting Room8
Mar12		Main Forum				Global Supply Chain Forum	Immunology Innovation Forum	Radiopharmaceutical Innovation Forum	Innovative Process Technology Forum
	09:00-10:00	BIOCHINA2026				/		/	
	10:00-11:00	Opening Ceremony				Opening Panel Discussion		Opening Panel Discussion	
	11:00-12:00	Networking	Networking	Networking	Networking	Networking	Networking	Networking	Networking
			BioBD Forum	Global Forum	Global Regulatory Forum	Global Supply Chain Forum	Immunology Innovation Forum	Radiopharmaceutical Innovation Forum	Innovative Process Technology Forum
	12:00-13:00	Main Forum	License & NewCo	Korea Market	US & European Markets	Global Supply Chain Development	Infection & Immunology	Advanced Technologies & Target Breakthroughs	Quality Analysis
	13:00-14:00								
	14:00-15:00	Networking	Networking	Networking	Networking	Networking	Networking	Networking	Networking
			BioBD Forum	Global Forum	Global Regulatory Forum	Global Supply Chain Forum	Immunology Innovation Forum	Radiopharmaceutical Innovation Forum	Innovative Process Technology Forum
	15:00-16:00		Innovative Drug Market Opportunities	Korea Market India Market	APAC & Emerging Market Regulations	Local Supply Chain Development	Autoimmune Diseases	R&D Process Development & Industrialization	Purification Forum
	16:00-17:00								
17:00-18:00									
Mar13		Main Forum	BiOFUNDING Forum	Global Forum	Global Clinical Forum	Global Key Indication Forum	Immunology Innovation Forum	CMC Going Global Forum	Innovative Process Technology Forum
	09:00-10:00	MNC Strategy Release	Global BIO Investment	Global Market	Country-Specific Clinical Development Strategies	Neurological Diseases	Tumor Immunology	US and EU Markets	Purification Forum
	10:00-11:00								
	11:00-12:00	Networking	Networking	Networking	Networking	Networking	Networking	Networking	Networking
			BiOFUNDING Forum	Global Forum	Global Clinical Forum	Global Key Indication Forum	Immunology Innovation Forum	CMC Going Global Forum	Innovative Process Technology Forum
	12:00-13:00	Strategic Release	Ecosystem & Innovation	LATAM Market Middle East Market	Country-Specific Clinical Development Strategies	Ophthalmic Diseases	Tumor Immunology	Emerging Markets	Analytical Testing
	13:00-14:00								
	14:00-15:00	Networking	Networking	Networking	Networking	Networking	Networking	Networking	Networking
			BiOFUNDING Forum	Global Forum	Global Clinical Forum	Global Key Indication Forum	Immunology Innovation Forum	Tech Transfer & GMP Manufacturing Forum	Innovative Process Technology Forum
	15:00-16:00		M&A & IPO & Early-Stage Investment	Russia Market	Clinical Development Strategies in China	Oncology Drugs	Immunodeficiency Diseases	Global Quality & Compliance	Pharmaceutical Excipients, Packaging And Delivery
	16:00-17:00								
17:00-18:00									
Mar14			Biopharma Finance, Tax and Legal Strategies Forum	Global Forum	Formulation Innovation Forum	Global Key Indication Forum	University Technology Transfer Forum	Tech Transfer & GMP Manufacturing Forum	Innovative Process Technology Forum
	09:00-10:00		Biopharma Finance & Legal	Emerging Markets Southeast Asian Market	Large Molecule Formulations	Infectious Diseases	University Translation Strategy & Top Level Design	Commercial Manufacturing	Cell Culture Forum
	10:00-11:00								
	11:00-12:00	Networking	Networking	Networking	Networking	Networking	Networking	Networking	Networking
			Global IP Forum	Global Forum	Formulation Innovation Forum	Global Key Indication Forum	University Technology Transfer Forum	Tech Transfer & GMP Manufacturing Forum	Innovative Process Technology Forum
	12:00-13:00		IP Strategic Planning	Emerging Markets Southeast Asian Market	Large Molecule Formulations Formulation Process And Manufacturing	Metabolic Disease Drugs Autoimmune Disease Drugs	Diversified Collaboration Models Avoiding Pitfalls & Maximizing Value	Regulatory Submissions Manufacturing Engineering & Smart Manufacturing	Cell Culture Forum Cleanroom And Engineering Equipment Forum
13:00-14:00									

BIOCHINA 2026 (11th Edition) Agenda

Mar12	Time	Meeting Room9	Meeting Room10	Meeting Room11	Meeting Room12	Meeting Room13	Meeting Room14	Meeting Room15
		Small Molecule Drug Innovation Forum		Antibody Drug Innovation Forum	In Vivo CAR-T Innovation Forum	Exosome Innovation Forum	BIOCHINA2026 Biomanufacturing Industry Forum	AI Innovation Forum
	09:00-10:00	/		/	/			/
	10:00-11:00	Opening Panel Discussion		Opening Panel Discussion	Opening Panel Discussion	Innovative Technologies	Agricultural Innovation	Opening Panel Discussion
	11:00-12:00	Networking	Networking	Networking	Networking	Networking	Networking	Networking
		Small Molecule Drug Innovation Forum	Nucleic Acid Innovation Forum	Antibody Drug Innovation Forum	In Vivo CAR-T Innovation Forum	Exosome Innovation Forum	BIOCHINA2026 Biomanufacturing Industry Forum	AI Innovation Forum
	12:00-13:00		Innovation And Development	Bispecific/MultispecificAntibody Innovation	Clinical Development	Innovative R&D & Clinical Translation	Biopharmaceutical Aesthetics	New Drug R&D
	13:00-14:00		Case Sharing					
	14:00-15:00	Networking	Networking	Networking	Networking	Networking	Networking	Networking
		Small Molecule Drug Innovation Forum	Nucleic Acid Innovation Forum	Antibody Drug Innovation Forum	In Vivo CAR-T Innovation Forum	Exosome Innovation Forum	BIOCHINA2026 Biomanufacturing Industry Forum	AI Innovation Forum
	15:00-16:00							
	16:00-17:00	Oncology Drugs	Process And Industrialization	Bispecific/MultispecificAntibody Innovation	Innovation & Development	Innovative R&D & Process Development	Food Developmen	Process & Manufacturing Optimization Clinical Development
17:00-18:00								
Mar13		Small Molecule Drug Innovation Forum	XDC Drug Innovation Forum	Antibody Drug Innovation Forum	In Vivo CAR-T Innovation Forum	Cell Therapy Innovation Forum	BIOCHINA2026 Biomanufacturing Industry Forum	Peptide Drug Innovation Forum
	09:00-10:00	Autoimmune Diseases	Process Development and CMC	Bispecific/MultispecificAntibody Innovation	Process & Quality	Future Manufacturing	Agricultural Innovation	Targets & Molecules
	10:00-11:00							
	11:00-12:00	Networking	Networking	Networking	Networking	Networking	Networking	Networking
		Small Molecule Drug Innovation Forum	XDC Drug Innovation Forum	Antibody Drug Innovation Forum	In Vivo CAR-T Innovation Forum	Cell Therapy Innovation Forum	BIOCHINA2026 Biomanufacturing Industry Forum	Peptide Drug Innovation Forum
	12:00-13:00							
	13:00-14:00	CNS	Process Development And CMC	Bispecific/MultispecificAntibody Innovation	Commercialization	Autoimmune Disease Drug Development	Biopharmaceutical Aesthetics	Indication Development
	14:00-15:00	Networking	Networking	Networking	Networking	Networking	Networking	Networking
		Small Molecule Drug Innovation Forum	XDC Drug Innovation Forum	Antibody Drug Innovation Forum	Stem Cell Therapeutics Innovation Forum	Cell Therapy Innovation Forum	BIOCHINA2026 Biomanufacturing Industry Forum	Peptide Drug Innovation Forum
	15:00-16:00	Anti-infectives						
	16:00-17:00	Metabolic Therapeutics	Differentiated Targets And Molecular Design	Upstream & Downstream Process Optimization	New Indications & Drugability Exploration	Solid Tumor Drug Development	Food Development	Process & Commercialization
	17:00-18:00	Cardiovascular Therapeutics						
Mar14		Innovative Nucleic Acid Drugs Forum	XDC Drug Innovation Forum	Early Research & Discovery Forum	Stem Cell Therapeutics Innovation Forum	Gene Therapy Innovation Forum	BIOCHINA2026 Biomanufacturing Industry Forum	Biomanufacturing Innovation Forum
	09:00-10:00	mRNA Development Case Sharing	Differentiated Targets And Molecular Design	Early Research & Discovery	New Indications & Drugability Exploration	Indication Development	Biosynthesis Technology	Traditional Chinese Medicine
	10:00-11:00							
	11:00-12:00	Networking	Networking	Networking	Networking	Networking	Networking	Networking
		Innovative Nucleic Acid Drugs Forum	XDC Drug Innovation Forum	Early Research & Discovery Forum	Stem Cell Therapeutics Innovation Forum	Gene Therapy Innovation Forum	BIOCHINA2026 Biomanufacturing Industry Forum	Biomanufacturing Innovation Forum
	12:00-13:00							
	13:00-14:00	mRNA Delivery and CMC Nucleic Acid Conjugates	Differentiated Targets And Molecular Design Commercial Manufacturing	Early Research & Discovery Early Research & Discovery	New Indications & Drugability Exploration Process & Quality	Technologies & Tools Technologies & Tools	Biological Fermentation Technology Gene Editing Technology	New Drugs Energy

About the Conference- Speaker

Track	Company	Name	Job Title
ADC	Bridge Biotherapeutics (Hangzhou) Co., Ltd.	Wei Ziping	Co-Founder, Chairman & CEO
ADC	Fosun Kite Biotech Co., Ltd.	Yang Xiaoming	Chief Technology Officer (CTO)
ADC	RemeGen	Zichen Qian	Director of Process Development
ADC	Multitude Therapeutics	Yan Jiaqing	Senior R&D Director
AI	XtalPi	Dr. Lipeng Lai	Co-founder and Chief Innovation Officer
AI	Insilico Medicine	Feng Ren	Co-CEO & CSO
Antibody	Innovent Biologics	Manyang Lin	Senior Director of Engineering Projects
Antibody	Process Development	Dongmei Han	General Manager
Antibody	Harbour BioMed	Terry Lu	Quality Director
Antibody	Qilu BioPharma	Ding Liu	Deputy General Manager
Antibody	Qilu Pharmaceutical Company	Yan Fang	Senior Director
Antibody	Shanghai Langrun Mabwell Biomedical Technology Co., Ltd.	An Wang	Quality Head
Antibody	3d-medicines	Charles Feng	Executive Director of Large Molecule CMC, Head of MAH Production Management
Antibody	Shanghai Huaota Biopharmaceutical Co., Ltd.	Cui Xiaopei	Senior Director of Technical Department
Antibody	Halobio	Bao Yanwen	Deputy Director (Upstream Process)
Antibody	Novatim Immune Therapeutics (Zhejiang) Co., Ltd.	Xianghai Cai	Vice President
Antibody	Shanghai Hengrui Pharmaceuticals Co, Ltd.	Zhou Kaimeng	Vice General Manager
Antibody	Cytocares	Yingfeng Huang	CEO
Antibody	BioRay Pharmaceutical Co., Ltd.	Zhu Wei	Chief Medical Officer (CMO)
Antibody	Antengene	Hou Bing	Executive Director of Early Drug Development
Antibody	Shanghai Mabgeek Pharmaceutical Co., Ltd.	Yuan	Director of Production and Quality Management
Antibody	Jiangsu T-mab Biopharmaceutical Co., Ltd	Dai Hu	Head of Quality & QP
Antibody	Junshi BioEngineering	Homer Zhang	Senior Director of Automation & Information
Antibody	Elpiscience	Andy Yang	RA Head, Director
Antibody	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.	Yubin Zhou	Vice President of Clinical Operations
Antibody	EpimAb Biotherapeutics, Inc.	Wu Xuan	Senior Director of Biotechnology Department
Antibody	INSTIL BIO (U.S. -based biotech company)	Lu YingQi	China CMO/SVP
Antibody	Shanghai Huaota Biopharmaceutical Co., Ltd.	Xiangyang Zhu	CEO
Antibody	BioRay Pharmaceutical Co., Ltd.	Dr. Haibin Wang	CEO
Antibody	HanchorBio Inc	Scott Liu, Ph.D.	Founder, Chairman, and CEO
Antibody	Gmax Biopharm LLC.	SHUQIAN JING	Founder, Chairman&CEO
Antibody	3D Medicine Inc	Carol Xia	VP & Board secretary
Antibody	Innolake Biopharm	Dr. Mingde Xia	Founder, Chairman, and CEO
Antibody	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.	Wenzhi Tian	Chairman, CEO and CSO
Antibody	WUHAN YZY BIOPHARMA CO., LTD.	Dr. Zhou Pengfei	Founder& Chairman &CEO
Antibody	CStone Pharmaceuticals	Dr. Jason YANG, MD, PhD.	CEO, President of R&D and Executive Director of the Board
Antibody	Biosion Inc.	Mingjiu Chen, PhD	Founder, President & CEO
Biomufacturing	Innovation Academy for Precision Measurement Science and Technology	Lichun He	Professor and Ph.D. Supervisor
Bispecific Antibody	Novatim	Dr. Guoxiang Wu	Founder, Chairman and CEO
Cell Therapy	FOSUNKAIROS	WENGSHI WANG	SVP
Cell Therapy	Juventas Cell Therapy Ltd.	Wang Yongzeng	Chief Technology Officer (CTO)
Cell Therapy	Imunopharm Technology Co. Ltd.	Qi Feifei	Cofounder & CTO
Cell Therapy	Shanghai Cell Therapy Group	Gao Haixia	Senior Director of Supply Chain
Cell Therapy	JW Therapeutics Ltd.	Ivan Lin	Head of Manufacturing/Head of MSAT&ATS
Cell Therapy	Simcere	Shuping Fang	Director
Cell Therapy	Leman Biotech	Dudu Tong	Executive Director
Cell Therapy	PRECISION BIOTECH	MEILING WANG	QC Lead

About the Conference- Speaker

Track	Company	Name	Job Title
Cell Therapy	Xinghua Bio	Hua Liu	Founder & Chief Scientific Officer
Cell Therapy	PersonGen BioTherapeutics(Suzhou) Co.,Ltd.	Fengtao You	Director Innovative drug research Institute
Cell Therapy	NaviGen Bio	Meijia Yang, PhD	Founder and Chairman
Cell Therapy	Nanjing AcrolImmune Biopharmaceutical Co. Ltd	Mingyang Gu	General Manager Assistant
Cell Therapy	PersonGen	Min Wang	VP
Cell Therapy	Base Therapeutics (Shanghai) Co, Ltd.	Lv Fenghua	Senior Director of CMC and Head of Quality
Cell Therapy	GRACELL	LJ Shen	SVP
Cell Therapy	Origincell Therapeutics	He Xiaowen	CSO
Cell Therapy	Bangyao Biotechnology Co., Ltd	Liang Su	Manufacturing Director
Cell Therapy	Unixell Biotech	Alex Wu	CMC sVP
Cell Therapy	AbelZeta	DONGYAO NI	MD SVP, GLOBAL BD & LICENSING AND CORPORATE AFFAIRS
Cell Therapy	Sino-cell Biomed Co., Ltd	Xinhua Zhang	VP of Quality
Cell Therapy	HRYZ Biotech Co.	Yanyan Han	CSO
Cell Therapy	Simnova	Wen Limin	SVP
Cell Therapy	Fosun Kairos	Xingrong Chen	CEO
Cell Therapy	Neukio Biotherapeutics	Wang Liqun	CEO
Cell Therapy	PersonGen BioTherapeutics (Suzhou) Ltd., Co.	Lin Yang	Founder/Chairman/CEO
CGT/Antibody	Zhejiang Provincial Drug Inspection Center	Tu Bing	Biological Products Inspector
Clinical	Zhongshan Hospital, Fudan University	Xiaowu Huang, PhD & MD	Director of the Biotherapy Center, Professor and Chief Physician of Hepatobiliary Oncology and Liver Transplantation, Zhongshan Hospital, Fudan University;
Clinical	Doma Biopharmaceutical (Suzhou) Co., Ltd.	Dr Rong Chen	Chief Medical Officer
Exosome	NewExo Biotechnology Co., Ltd	Haoran Wang	CEO
Exosome	Echo Biotech Co., Ltd, Beijing	Libo Zhao	Chief Technology Officer & Co-founder
Exosome	Shandong Qilu Cell Therapy Engineering Technology Co., Ltd.	SHUANGSHUANG YANG	R&D Project Manager
Exosome	Tingo Exosomes Technology Co.,Ltd	Xiaohu Ge	Chairman
Gene Therapy	Kanglin Biotech	XUDONG ZHU	Quality Director
Gene Therapy	Exegenesis Bio Inc.	Zhenhua Wu	Founder and CEO
Investment & Finance	OrbiMed	Daniel Ying	Executive Director
MNC	Gilead Sciences Shanghai Pharmaceutical Technology Co., Ltd	Zig LANG	Vice President and Head of International Medical Affairs and APAC Oncology Development, China Development Site Head
mRNA	Suzhou HealiRNA Biotechnology Co.,Ltd.	Zhong Chen	VP
Nucleic Acid	Tricision Biotherapeutics. Inc	Li ShiYou	Co-founder/CTO
Nucleic Acid	Axter Therapeutics	Sunny Huang	VP
Nucleic Acid	Shanghai Huanma Biopharmaceutical Co., Ltd.	Yang Yun	Chairman&CTO
Nucleic Acid	Theorna	Lin Qingshu	CMC Director
Nucleic Acid	Ningbo Vigor Biologics Inc	Changyun Xiong	CEO
Nucleic Acid	WestGene Biopharma	Xiangrong Song,	CEO & Scientific Co-founder
Nucleic Acid	CirCode Biomed	Dr. Chenxiang Tang	CEO
Nucleic Acid	Abogenbio	Dr. Bo Ying	Founder, Chairman and CEO
Nucleic Acid	Youjia (Hangzhou) Biomedical Technology CO.,LTD	Lulu Fu	Director of Pharmaceutical Formulations
Peptide	Shanghai Minwei Biotechnology Co.,LTD	Wen-Xin Song	Deputy general manager
Peptide	Coherent Biopharma (Suzhou) Co., Ltd.	Jun Shao	Chief Technology Officer
Peptide	Shenzhen ScienCare Pharmaceutical Co., Ltd	Vincent Qu	Chief Technology Officer
Peptide	Shenzhen Sungening Biologicals Ltd.	Chester Yuan	Co-Funder/CSO
Peptide	Gan & Lee Pharmaceuticals	Wei Chen	Chairman, President, and Chief Executive Officer
Peptide	The United Laboratories	Cao Chunlai	General Manager
Peptide	Hangzhou Jiuyuan Gene Engineering Co.,LTD	Wang Tongying	Technical Director
Peptide	VISEN Pharmaceuticals	Jing Zhu	CMC VP
Peptide	Fosun Pharma Global R&D	Song Yang	Vice President, Head of CNS & Immunology

About the Conference- Speaker

Track	Company	Name	Job Title
Pharma	Sino Biopharmaceutical Limited	Mr. Tse Hsin	Executive Director, Senior Vice President, Member of the Executive Board Committee
Pharma	Qilu Pharmaceutical	Tao Weikang	Director, Vice President, and General Manager of Global Innovation R & D System of Qilu Pharmaceutical Group
Polyclonal Antibody/ADC	VelaVigo	Li Jing	Founder and CEO
Radiopharmaceutical	BoomRay	Bo Shan	Chief Executive Officer (PhD)
Radiopharmaceutical	Shanghai Institute of Materia Medica Chinese Academy of Sciences	Zhen Cheng	Professor and Director of Molecular Imaging Center
Radiopharmaceutical	Chengdu StarRay Therapeutics Co., Ltd	David Chen	President&CSO
Radiopharmaceutical	BoomRay Pharmaceutical Co., Ltd.	Andy	QA Assistant Director
Research & Government	Shanghai Institute for Drug Control (SIFDC)	CHEN GANG	Chief Pharmacist
Small Molecule	AstraNeura, Co., LTD.	Xianbo Zhou	Founder&CEO
Small Molecule	Synrx	HU HE	VP
Small Molecule	Degron Therapeutics Inc.	Lily Zou	Co-Founder and CEO
Small Molecule	Fosun Pharma / Novaonco Co., Ltd.	YU XIAOHONG	Co-CSO / Chairman
Small Molecule	IRCBC, SIOC, Chinese Academy of Sciences	Yelin Chen	Principal Investigator
Small Molecule	JOYO Pharma	Lei Li	Senior Director of PPM
Small Molecule	HKUST / EnKang Pharmaceuticals (Guangzhou) , Ltd.	Prof. LIANG Chun	Founder & CSO
Small Molecule	Signet Therapeutics	Zhang Haisheng, Ph.D.	Founder and CEO
Small Molecule	Shanghai CureGene Pharmaceutical Co.	Xiaowu Chen	Vice President, Chemistry
Small Molecule	HaiHe Pharmaceuticals Inc.	Fugen Li	SVP (Translational Medicine)
Small Molecule	CGeneTech(Suzhou,China)Co.,Ltd.	Jiahong Zhao	CMO
Small Molecule	Allorion Therapeutic	Zhen Liu	VP
Small Molecule	Pfizer (China) Research and Development Co., Ltd.	MENG QIAO	Director
Small Molecule	Evopoint Biosciences Co., Ltd	Fred Hu, Ph.D.	CTO, Co-Founder
Small Molecule	Phaeno Therapeutics	Qin Donghui	Chairman & CEO
Small Molecule	Ranok Therapeutics(Hangzhou) Co., Ltd.	WEIWEN YING	CEO
Small Molecule	Salubris Pharmaceuticals	Jane Wang	CSO
Small Molecule	Degron Therapeutics	Julia Dou	Director
Small Molecule	Haihe Biopharma	Dr. Guo Xiaoning	CMO
Small Molecule	NeuShen Therapeutics	Joan (Huaqiong) Shen	Founder and CEO
Small Molecule	CGeneTech(Suzhou,China)Co.,Ltd.	John Yu	CEO
Sourcing	Remegen.cn	jinxi jia	Executive Director (Supply Chain Management Department)
Stem Cell	HELP Therapeutics	S	Co-founder&CTO
Stem Cell	Nuwacell Biotech Co., Ltd. (Guangzhou, China)	Dong Chengyou	GM Assistant
Stem Cell	Qilu Cell Therapy	Tan Yi	VP and R&D Director
Stem Cell	Hangzhou Institute for Advanced Study, UCAS	Cheguo Cai	Vice Dean for School of Life and Health Sciences
Stem Cell	HemaCell Biotechnology Inc.	Fangfang Zhu	CEO
Stem Cell	HELP Therapeutics	YONGSHENG XU	Co-founder&CTO
Stem Cell	Nuwacell Biotech Co., Ltd. (Guangzhou, China)	Dong Chengyou	GM Assistant
Stem Cell	Qilu Cell Therapy	Tan Yi	VP and R&D Director
XDC	MediLink Therapeutics	Tony Xue	Chairman & CEO
XDC	-	Ziping Wei	Co-founder, Chairman, and CEO
Small Nucleic Acid	Youjia Bio	Zhao Chengjiang	Director of the Nucleic Acid Drug Research Institute
Small Nucleic Acid	ChainGen Bio	Xuefeng Zhang	Co-founder & COO
Small Nucleic Acid	Visirna Therapeutics	You Dong	Head of Clinical Development
Small Nucleic Acid	Haichang Biotech	Bai Jun	Head of Small Nucleic Acid Department
Small Nucleic Acid	AnlongBio/AnlongMed	Chunlin Zhao, Ph.D	Founder
Small Nucleic Acid	Youjia Bio	Cui Wenhao	CEO
Other Areas	China Insights Consultancy (CIC)	Glenn (Xuchao) Hou	Founding Partner

BIOCHINA2026 Main Forum

Date	March 12th	March 13th
09:00-14:00	09:00-09:20 BIOCHINA Opening Ceremony 09:20-10:00 BIOCHINA Opening Speech	09:00-11:00 MNC Strategy Release
	9:40-10:40 Panel Discussion: Disruptive Innovation – Global Insights 10:40-11:10 Presentation: Biotech Opportunities In The AI Era 11:10-11:40 Presentation: Biotech Innovation From Clinical Practice	11:00-12:00 Panel Discussion: Co-Creating a Collaborative Ecosystem with Global Partners
	11:40-12:00 BIOCHINA Awards	12:00-13:00 Strategic Release
	12:00-12:50 Panel Discussion: AI in Biopharma 12:50-13:40 Panel Discussion: How Can Chinese Pharma Companies Embrace Globalization?	13:00-14:00 Strategic Release
Concurrent Events	March 12, 18:00-20:00 BIONIGHT 2026 (Invitation Only) March 12-14 BiOPartnering 1V1 Meetings March 12-14 BIOCHINA2026 Exhibition	

BIOCHINA2026 BioBD Forum

BIOCHINA2026 BioFUNDING Forum

BIOCHINA2026 Global IP Forum

Date

March 12th

March 13th

March 14th

09:00-11:00

Exhibition Hall Closed During Opening Ceremony

BioFUNDING Forum

09:00–09:20 Presentation: Global Biopharma Investment Trends

09:20–10:10 Panel Discussion: 2026 Key Themes in Biotech Investment

10:10–11:00 Panel Discussion: How China's Dual-Currency Healthcare Funds Invest Overseas

09:00–11:00 Compliance-Driven Value: Tax & Legal Strategies for Biopharma Companies

11:00-12:00

Lunch & Networking

Lunch & Networking

12:00-14:00

BD Strategy

12:00–12:30 Presentation: Insights On BD Deals For Chinese Innovative Drugs And Global Enablement

12:30–13:15 Presentation: MNC Asia-Pacific Strategy

13:15–14:00 Presentation: Global Strategies Of Chinese Big Pharma & Biotech

Speaker: Vivian Feng, Business Development Department General Manager, Shanghai Fosun Pharmaceutical (Group) Co., Ltd

12:00–13:00 LP–GP–Biotech Ecosystem: Aligning Policy, Capital, and Innovation

13:00–14:00 Pharma Incubators: Innovation Outposts and Win-Win Models

14:00-15:00

Networking & Events

Networking & Events

15:00-18:00

15:00–16:00 NewCo Evolution & MNC–China Collaboration

Market Outlook

16:00–16:40 China Market: New Opportunities & Strategies

16:40–17:20 Global Expansion: China's Innovation Pathways

17:20–18:00 Reimbursement Strategies for Innovative Drugs

15:00–16:00 Industry Investment Outlook: Alliances and Strategic M&A

16:00–17:00 After the Boom: Value Reset in the IPO 2.0 Era

17:00–18:00 Back to the Source of Innovation: Investing Early, Small, and New

BIOCHINA2026 Global Forum

Date	March 12th	March 13th	March 14th
09:00-11:00	Exhibition Hall Closed During Opening Ceremony	Global Market 09:00-09:10 Opening Presentation 09:10-09:50 Pharma Strategic Alliance Panel 09:50-10:50 CGT Panel	Middle East Market 9:00-9:30 Panel Discussion : Regional Regulations, market entry strategies, and pharma business development in Middle East LATAM Market 10:00-10:30 Panel Discussion: Focus Business Development, Licensing, and Collaboration Opportunities with Latin American Pharma Companies 10:30-11:00 panel Discussion: Clinical & Supply Chain Opportunities
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	Korea Market 12:00-12:20 Opening Keynote Presentation – Highlight Capital Speaker: Lee, Highlight Capital, Principle 12:20-13:20 Panel Discussion – China-Korea Collaboration Opportunities Speaker: Lee, Highlight Capital, Principle Open Innovation Center, Celltrion Inc Hun Kim, SK Bioscience, President Soyong Jang, R&D Business Development Director, Celltrion Inc 13:20 – 14:00 Panel Discussion – Pharma Market Access and Regulatory Strategies	LATAM Market 12:00-13:00 Panel Discussion: Focus Business Development, Licensing, and Collaboration Opportunities with Latin American Pharma Companies Speaker: Joao Siffert, Eurofarm, Head of R&D, CEO, Director. Middle East Market 13:00-13:20 Keynote Presentation – Middle East Ecosystem Landscape 13:20-14:00 Panel Discussion: Regional Regulations, market entry strategies, and pharma business development in Middle East Speaker: Lulu Manasseer, Alnylam Pharmaceuticals, Inc, Business Consultant and Principal Associate Scientist. Joe Henein, NewBridge Pharmaceuticals	Emerging Market 09:00-10:00 Panel Discussion- Emerging regions & Belt & Road Collaboration Clinical , Production & Supply Chain Opportunities in emerging Belt & Road Regions Speaker: Dr. Obaidullah, phd, Drug Regulatory Authority of Pakistan (DRAP), CEO. Dr. Akhtar Abbas khan, National Pharmacovigilance Center, Drug Regulatory Authority of Pakistan (DRAP), Director of Pharmacy Services & Head. Southeast Asian Market
14:00-15:00	Networking & Events	Networking & Events	
15:00-18:00	Korea Market 15:00 – 15:40 Panel Discussion – Biotech Collaboration: BD and Co-development Models Speaker: Nam-Gu Her, AIMED BIO, CEO Nari Yun, GI INNOVATION, Vice president India market 16:00-16:20 Keynote Presentation 16:20-17:20 Panel Discussion – BD Collaboration between China and India Speaker: Mayur Sangwai, Dr. Reddy's Laboratories, Head BD - Innovation Licensing. Manoj Thombare, Sun Pharma Laboratories Ltd, Senior General Manager and Business Development & Licensing. 17:20-18:00 Panel Discussion – Supply Chain Collaboration between China and India Speaker: Dr. SAMBASHIVA D, Abhignya Biotech Pvt Ltd, Founder.	Russia Market 15:00-15:20 Opening Remarks 15:20-16:20 Panel Discussion- BD & Licensing Announcements Speaker: Alexander Nozdrachev, BinnoPharma, Managing Partner of Innovant Bio. Svetlana Bolsheva, BinnoPharma, Strategy & Business Development Director. Vera Mymirna, Geropharma, BD specialist Business Development. Alexandr Gorynin, Nanolek, BD AND M&A director, Nizhpharm Artem Ahn, BD and Strategy Director. Igor Borisenko, R-pharm, Retail Director. 16:20-17:20 Innovation and Supply Chain collaboration 17:20- 17:40 Q&A	
Concurrent Events	March 12th–14th BIOCHINA2026Exhibition March 12th 18:00-20:00 BIONIGHT 2026 (Invite-only)	March 12th–14th BiOPartnering 1V1 Meetings March 13th 18:00-20:00 Networking Reception	8

BIOCHINA2026 Global Regulatory Forum		BIOCHINA2026 Global Clinical Forum	BIOCHINA2026 Formulation Innovation Forum
Date	March 12th	March 13th	March 14th
09:00-11:00	Exhibition Hall Closed During Opening Ceremony	Post-BD Clinical Strategy 09:00–10:00 Panel Discussion: Global Clinical Pathways For Chinese Innovative Drugs – Post-License Out Strategies And Collaboration 10:00–10:30 Presentation: TBC 10:30–11:00 Presentation: TBC	Large Molecule Formulations 09:00–10:00 ADC Subcutaneous Formulation Case Sharing 10:00–11:00 ADC Lyophilized Formulations
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	US & European Markets 12:00–13:00 United States 13:00–14:00 Europe	Global Multi-Region Clinical Development 12:00–12:20 Presentation: Clinical Submission Strategies Across Multiple Regions 13:00–14:00 Panel Discussion: Global Clinical Strategy For Chinese Innovative Drugs Innovative Therapy Clinical Models 13:00–13:20 Presentation: TBC 13:20–14:00 Panel Discussion: How IIT Studies Can Accelerate Approval And Serve As Catalysts For Innovative Therapies	Large Molecule Formulations Formulation Development Case Sharing 12:00–12:20 Presentation: Antibody Subcutaneous Formulation Development High-Concentration/Ultra-High-Concentration Antibody Formulations
14:00-15:00	Networking & Events	Networking & Events	Formulation Process And Manufacturing 14:00–15:00 Formulation Process Optimization 15:00–16:00 Formulation Process Manufacturing
15:00-18:00	APAC & Emerging Market Regulations 15:00–16:00 Global 16:00–17:00 Indonesia 17:00–18:00 Saudi Arabia	Overseas Projects China Clinical Development Strategy 15:00–16:00 China Market Characteristics And Clinical Strategies 16:00–17:00 Case Studies Of Overseas Projects In China Clinical Development 17:00–18:00 Collaboration Models And Risk Management	

BIOCHINA2026 Global Supply
Chain Forum

BIOCHINA2026 Global Key Indication Forum

Date

March 12th

09:00-11:00

Exhibition Hall Closed During Opening
Ceremony**Neurological Diseases**

09:00-10:00 R&D

10:00-11:00 CNS From A Clinical Perspective

Infectious Diseases

09:00-10:00 R&D

10:00-11:00 R&D

11:00-12:00

Lunch & Networking

12:00-14:00

Global Supply Chain Development12:00-13:00 Overseas Supply Chain
Compliance13:00-14:00 Overseas Supply Chain
Development**Ophthalmic Diseases**

14:00-15:00 R&D

15:00-16:00 Clinical

Metabolic Disease Drugs

12:00-13:00 R&D

13:00-14:00 Clinical

14:00-15:00

Networking & Events

15:00-18:00

Local Supply Chain Development15:00-16:00 Cost Reduction and Efficiency
ImprovementSpeaker: [Gao Haixia, Senior Director of Supply
Chain, Shanghai Cell Therapy Group](#)

16:00-17:00 Local Substitution

17:00-18:00 Supply Chain Stability

Oncology Drugs

15:00-16:00 R&D

16:00-17:00 Clinical

17:00-18:00 Industry

Autoimmune Disease Drugs

14:00-15:00 R&D

15:00-16:00 Clinical

BIOCHINA2026 Immunology Innovation Forum

BIOCHINA2026 University Technology Transfer Forum

Date	March 12th	March 13th	March 14th
09:00-11:00	Exhibition Hall Closed During Opening Ceremony	09:00–11:00 Tumor Immunology	09:00–11:00 University Translation Strategy & Top-Level Design Why University Translation Is The Lifeline Of Life Sciences Building The “Highway” For Translating Academic Achievements Clinical-Driven Innovation: The Fast Track For Translation
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	12:00–14:00 Infection & Immunology	09:00–11:00 Tumor Immunology	12:00–14:00 Diversified Collaboration Models Pros, Cons, And Practical Use Of Option-to-License Models Sustainable Approaches To Joint Labs And Innovation Centers Which Collaboration Model Fits Your Stage Best? 14:00–16:00 Avoiding Pitfalls & Maximizing Value “Devil In The Details” In Technology Transfer Contracts Identifying “Good Projects” And “Good Deals” From Scientist And Investor Perspectives Mapping A New Blueprint For Efficient Life Science Translation In China
14:00-15:00	Networking & Events	Networking & Events	
15:00-18:00	15:00–18:00 Autoimmune Diseases	15:00–18:00 Immunodeficiency Diseases	

BIOCHINA2026 Radiopharmaceutical Innovation Forum		BIOCHINA2026 CMC Going Global Forum		BIOCHINA2026 Global Tech Transfer & Compliance Forum	
Date	March 12th	March 13th		March 14th	
09:00-11:00	Exhibition Hall Closed During Opening Ceremony	US and EU Markets 09:00–10:00 CMC Global Registration Strategies: FDA/EMA Submissions And Pharmaceutical Documentation 11:00–12:00 CMC Regulatory Review, Approval, And Audits		Commercial Manufacturing: Large-Scale Antibody Production / Multi-Product Co-Processing 09:00–09:20 Presentation: TBC 09:20–09:40 Presentation: Large-Scale Production Insights Commercial Manufacturing & Inspection 10:00–10:20 Presentation: Addressing Pre-Commercialization Challenges From Process Validation 10:20–10:40 Presentation: Data Integrity And Case Studies In Domestic Manufacturing Inspections 10:40–11:00 Presentation: Contamination Control Strategies From Validation Management Perspective	
11:00-12:00	Lunch & Networking	Lunch & Networking		Lunch & Networking	
12:00-14:00	Advanced Technologies & Target Breakthroughs 12:00–13:00 Technology Breakthroughs 13:00–14:00 Collaborative Innovation	Emerging Markets 12:00–13:00 Belt & Road / Southeast Asia: Regulatory Submissions And CMC Oversight 12:00-12:20 Presentation: Going Global – UAE 13:00-14:00 Presentation: Regulatory Submission & CMC Requirements in Global & Korea		Regulatory Submissions: Domestic & International Strategies 12:00–12:20 Presentation: Global Submission Strategies – China, US & EU 12:20–12:40 Presentation: Pharmaceutical Changes During Clinical Trials & Coordinated Submissions in China, US & Australia 12:40–13:00 Presentation: Smart Submissions: AI Applications And Regulatory Considerations From IND To NDA 13:00–14:00 Panel Discussion: Managing Domestic And International Pharmaceutical Submissions And Changes	
14:00-15:00	Networking & Events	Networking & Events		Manufacturing Engineering & Smart Manufacturing 15:00–15:20 Presentation: Smart Biopharmaceutical Factories 15:20–15:40 Presentation: ADC Facility Development Insights 15:40–16:00 Presentation: Facility Strategy – From Assessment to Construction GMP Compliance: FDA / EMA / NMPA Case Studies: Implementing Smart Manufacturing in Biologics	
15:00-18:00	R&D Process Development & Industrialization 15:00–16:00 Early Development Innovations Alpha-Emitter Early R&D Radiopharmaceutical Ligand Development 16:00–17:00 CMC & Commercial Manufacturing 17:00–18:00 Clinical PI Face-to-Face	BIOCHINA2026 Global Tech Transfer & Compliance Forum Global Quality & Compliance: International Standards and Compliance Systems 16:00–16:20 Presentation: Quality Insights 16:20–16:40 Presentation: Differences in Antibody Drug Quality Standards from IND to BLA 16:40–17:00 Presentation: Quality Research Quality Change Management & Technology Transfer 17:00–17:20 Presentation: Lifecycle Change Management 17:20–17:40 Presentation: Post-Market Quality Changes 17:40–18:00 Presentation: TBC			

BIOCHINA2026 Innovative Process Technology Forum

Date	March 12th	March 13th	March 14th
09:00-11:00	Exhibition Hall Closed During Opening Ceremony	Purification Forum Virus Clearance Post-Marketing Process Changes And Compliance 10:00–10:20 Presentation: TBC 10:20–10:40 Presentation: Chromatography Media Related	Cell Culture Forum Cell Line Development And Expression System Optimization 9:00–9:20 Presentation: Cell Line Development Related 3D Cell Culture And Construction Establishment And Validation Of Cell Culture Models Cell Culture Quality And Compliance
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	Quality Analysis ADC Full Lifecycle Quality Control System Establishment 12:00–12:20 Presentation: ADC Drug Quality Research 12:20–12:40 Presentation: ADC Quality Method Validation 13:00–14:00 Quality Analysis – Agilent Special Session	Analytical Testing Innovation And Advanced Applications In Testing 12:00–12:20 Presentation: Antibody Quality Control Techniques 12:20–12:40 Presentation: Process Residuals Quality Control And Analysis Strategies Lifecycle Testing Compliance And Validation 13:00–14:00 Panel Discussion: Antibody Analytical Method Development And Validation Under The New Chinese Pharmacopoeia With Case Sharing	Cell Culture Forum 12:00–13:00 Scale-up of Cell Culture Processes 13:00–14:00 Large-Scale Cell Culture Technologies and Applications
14:00-15:00	Networking & Events	Networking & Events	Cleanroom And Engineering Equipment Forum 14:00–15:00 Quality Assurance System For Cleanroom Engineering And Equipment 15:00–16:00 Digitalization And Efficiency Optimization Of Engineering Equipment
15:00-18:00	Purification Forum HCP Impurity Removal Biologics Separation And Purification Technology Purification Process Characterization Development And Scale-Up Of Biologics Purification Processes	Pharmaceutical Excipients, Packaging And Delivery Innovation In Delivery Systems 15:00–15:20 Presentation: Functionality And Clinical Safety Of Inhalation Delivery Devices 16:00–17:00 Compatibility And Compliance 17:00–18:00 Development And Application Of Novel Biologics Excipients	

BIOCHINA2026 Small Molecule Drug Innovation Forum
BIOCHINA2026 Innovative Nucleic Acid Drugs Forum

Date	March 12th	March 13th	March 14th
09:00-11:00	Exhibition Hall Closed During Opening Ceremony	CMC and Analytical Method Development 09:00-10:00 Case Sharing: Small Molecule Autoimmune Innovative Drug Development	mRNA Development Case Sharing 09:00-10:00 Case Studies in mRNA Vaccine Development 10:00-11:00 Case Studies in mRNA Drug Development
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	Breakthroughs and Challenges of “Undruggable” Targets 12:00-13:00 Case Sharing: Small Molecule Oncology Innovative Drug Development	Small Molecule Formulation Improvement & Solubility Enhancement Innovations	mRNA Delivery and CMC 12:00-13:00 Delivery Optimization 13:00-14:00 CMC Strategies
14:00-15:00	Networking & Events	Networking & Events	Circular RNA 14:00-15:00 Circular RNA Design and CMC Nucleic Acid Conjugates 15:00-16:00 Nucleic Acid Conjugate Development
15:00-18:00	CIP Protein Degradation Technology 15:00-16:00 Panel Discussion: Overcoming “Undruggable” Targets 16:00-16:20 Presentation: Non-Protein Degradation Molecules 16:20-16:40 Presentation: Protein Degradation Molecules 16:40-17:00 Presentation: Protein Degradation Molecules	Tumor & Autoimmune Drug Development Case Studies 15:00-16:00 Clinical-Driven Autoimmune Drug Development 16:00-17:00 Innovative Targets & Molecules for Small Molecule Oncology Drugs Process Validation & Commercial Production	

BIOCHINA2026 Nucleic Acid Innovation Forum

BIOCHINA2026 XDC Drug Innovation Forum

Date	March 12th	March 13th	March 14th
09:00-11:00	Exhibition Hall Closed During Opening Ceremony	Process Development and CMC 9:00-10:00 Panel Discussion: From China to the World – ADC CMC Development Strategies and Global Expansion ADC Process Characterization and Validation 10:00-10:20 Presentation: TBC 10:20-10:40 Presentation: CMC Studies of Bispecific ADCs 10:40-11:00 Presentation: TBC	Differentiated Target and Molecule Design ADC Autoimmune Track 9:00-9:20 Presentation: ADC Development And Clinical Progress In Autoimmune Diseases Bispecific/Toxin ADC Development 10:00-10:20 Presentation: Bispecific Toxin ADC Development
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	Innovation And Development Case Sharing Small Nucleic Acid Clinical Development 12:00-12:20 Presentation: siRNA Drug Clinical Development Strategies And Clinical Data Overview 12:20-12:40 Presentation: Clinical Development And Progress Of siRNA Drugs In Cardiovascular/Metabolic Diseases 12:40-13:00 Presentation: Clinical Development And Progress Of siRNA Drugs In Non-Cardiovascular/Metabolic Diseases 13:00-14:00 Panel Discussion: Delivery Challenges And Design Optimization	Process Development And CMC 12:00-13:00 Bispecific ADC Process Development At IND And BLA Stages 13:00-14:00 Process Development Technology Innovation And Applications	Differentiated Target and Molecule Design ADC Innovative Targets & Technology Development From Preclinical To Clinical And Clinical Translation 13:00-13:20 Presentation: ADC Clinical R&D Differentiated Development 13:20-13:40 Presentation: ADC New Technology Applications And Clinical Translation 13:40-14:00 Presentation: ADC Clinical Development
14:00-15:00	Networking & Events	Networking & Events	Commercial Manufacturing 14:00-15:00 ADC Co-Line Production 15:00-16:00 ADC Segmented Production
15:00-18:00	Process And Industrialization 15:00-16:00 Process Development And CMC Speakers: Xizhao Wang, CMC R&D, Rebo Biopharma 16:00-17:00 Analysis And Quality 17:00-18:00 Scale-Up Manufacturing	Differentiated Targets And Molecular Design Complex ADC Molecule Development 15:00-15:20 Presentation: ADC Development 15:20-15:40 Presentation: ADC Development 16:00-17:00 Panel Discussion: Bispecific/Multispecific ADC Differentiated Design, Linker-Payload Innovation And Global Collaboration	

BIOCHINA2026 Antibody Drug Innovation Forum

BIOCHINA2026 Early Research & Discovery Forum

Date	March 12th	March 13th	March 14th
09:00-11:00	Exhibition Hall Closed During Opening Ceremony	Bispecific/Multispecific Antibody Innovation 09:00-10:00 Panel Discussion: Exploration of Bispecific /Multispecific Antibody R&D and Clinical Development from a Global Innovation Collaboration Perspective Autoimmune 10:00-10:20 Presentation: TBC 10:20-10:40 Presentation: TBC	Early Research & Discovery 09:00-10:00 Early Research & Discovery 10:00-11:00 Early Research & Discovery
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	Bispecific/Multispecific Antibody Innovation Bispecific Antibody Innovation and Clinical Development 12:00-12:20 Presentation: TBC 12:00-12:40 Presentation: Progress and Clinical Development of PD-1/VEGF Bispecific Antibodies 12:40-13:00 Presentation: TBC 13:00-14:00 Panel Discussion: TBC	Antibody Development & Clinical Research by Target 12:00-12:20 Presentation: Bispecific Antibody Design & Validation Antibody Development & Clinical Research by Indication	Early Research & Discovery 12:00-13:00 Early Research & Discovery 13:00-14:00 Early Research & Discovery
14:00-15:00	Networking & Events	Networking & Events	Early Research & Discovery 14:00-15:00 Early Research & Discovery 15:00-16:00 Early Research & Discovery
15:00-18:00	Bispecific/Multispecific Antibody Innovation Complex Molecule Innovation and Clinical Development 15:00-15:20 Presentation: Development of Novel NKCEs 15:20-15:40 Presentation: Preclinical Development of TCEs Multispecific Antibody Innovation and Clinical Development 16:00-16:20 Presentation: Trispecific TCEs	Upstream & Downstream Process Development and Optimization Antibody Process Development Case Focus 15:00-15:20 Presentation: TBC 15:20-15:40 Presentation: Considerations in Upstream Process Development for Antibodies 15:40-16:00 Presentation: Bispecific Antibody Process Development at IND Stage 16:00-17:00 Panel Discussion: Process Development and Lifecycle Management under Global Compliance 17:00-17:30 QbD-Driven Continuous Flow Process Validation and RTRT Implementation 17:30-18:00 Smart Scale-Up and PPQ Verification from Lab to Commercialization	

BIOCHINA2026 In Vivo CAR-T Innovation Forum		BIOCHINA2026 In Vivo CAR-T Innovation Forum		BIOCHINA2026 Stem Cell Therapeutics Innovation Forum	
Date	March 12th	March 13th		March 14th	
09:00-11:00	Exhibition Hall Closed During Opening Ceremony	Process & Quality 12:00–13:00 Panel Discussion: Nonclinical and CMC Considerations from IND Submission Perspective Process Development & Quality Analysis 13:00–13:20 Presentation: Selection and Process Development of In Vivo Cell Therapy Vectors 13:20–13:40 Presentation: Quality Standards for In Vivo CAR-T from a Regulatory Perspective 13:40–14:00 Presentation: Analytical Method Development and Quality Studies		iPSC Early Research Track 09:00–09:20 Presentation: Clinical Progress of iPSC Therapy for Heart Failure 09:20–09:40 Presentation: Cell Therapy for Parkinson’s Disease – Clinical Validation of Next-Generation Therapies and Global Progress 09:40–10:00 Presentation: TBC 10:00–10:20 Presentation: Latest Clinical Progress of Fibroblast Therapy for DDD iPSC Process Challenges & Quality Control Track 11:20–11:40 Presentation: TBC 11:40–12:00 Presentation: TBC	
	10:00-11:00 Opening Panel				
11:00-12:00	Lunch & Networking	Lunch & Networking		Lunch & Networking	
12:00-14:00	Clinical Development 09:00–10:00 Presentation: First-in-Human CAR-T Therapy for Multiple Myeloma – Clinical Practice and Insights 09:20–09:40 Presentation: From Hematologic Malignancies to Autoimmune Diseases 09:40–10:00 Presentation: Clinical Translation Prospects of LNPs and Non-Viral Vectors 10:00–10:20 Presentation: First-in-Human (FIH) Study Design 10:20–10:40 Presentation: IND Submission Pathways and Regulatory Considerations for In Vivo CAR-T 10:40–11:00 Presentation: Anticipating and Managing In Vivo CAR-T Safety	Commercialization 12:00–12:20 Presentation: Market Positioning and Clinical Value 12:20–12:40 Presentation: Insights from First-in-Human Clinical Data and Commercial Implications 12:40–13:00 Presentation: Innovative Pricing and Reimbursement Strategies for In Vivo CAR-T 13:00–13:20 Presentation: Market Access and Localization Strategies for In Vivo CAR-T in Emerging Markets 13:20–13:40 Presentation: Scale-Up Production and Supply Chain Challenges for In Vivo CAR-T 13:40–14:00 Presentation: IND Submission and Review Considerations for In Vivo CAR-T		MSC Development Track 12:00–12:20 Presentation: Phase III Clinical Trial Design of MSC for Knee Osteoarthritis 12:20–13:00 Panel Discussion: Clinical Design Considerations and Regulatory Standards for Knee Osteoarthritis 13:00–13:20 Presentation: Latest Progress and Quality Control of iMSC for Anti-Inflammation and Repair 13:20–13:40 Presentation: Gene-Modified MSC Therapy for Type 2 Diabetes – Latest Progress 13:40–14:00 Presentation: Clinical Progress and International Development Pathways of MSC Therapy for Acute Ischemic Stroke 14:00–14:20 Presentation: Latest Clinical Progress of MSC Therapy for Liver Cirrhosis 14:20–14:40 Presentation: Clinical Exploration of MSC Therapy for Liver Failure 14:40–15:00 Presentation: MSC Quality Control Strategies and Analytical Methods 15:00–16:00 Panel Discussion: Opportunities and Challenges for Stem Cell Drug Development under Regulation 818	
14:00-15:00	Networking & Events	Networking & Events			
15:00-18:00	Innovation & Development 15:00–16:00 Panel Discussion: In Vivo CAR-T R&D Progress and Development Prospects Speakers: 16:00–17:00 Lentiviral Vector In Vivo CAR-T R&D mRNA-LNP Delivery Vector In Vivo CAR-T R&D 17:00–17:20 Presentation: TBC 17:20–17:40 Presentation: TBC 17:40–18:00 Presentation: TBC	BIOCHINA2026 Stem Cell Therapeutics Innovation Forum			
		Stem Cell Industry Policies and Translational Practice 15:00–15:20 Presentation: Regulatory Policies 15:20–15:40 Presentation: Lecheng Pilot Program 15:40–16:00 Presentation: Industrialization 16:00–16:20 Presentation: Drug Development for Autoimmune Diseases 16:20–16:40 Presentation: Drug Development for Nervous System Diseases 16:40–17:00 Presentation: Drug Development for Respiratory System Diseases 17:00–18:00 Panel Discussion: Bridging Technology, Clinical Practice, and Regulation – Pathways to Commercialization of Innovative Stem Cell Drugs			

BIOCHINA2026 Exosome Innovation Forum		BIOCHINA2026 Cell Therapy Innovation Forum	BIOCHINA2026 Gene Therapy Innovation Forum
Date	March 12th	March 13th	March 14th
09:00-11:00	Exhibition Hall Closed During Opening Ceremony	Future Manufacturing 09:00–10:00 Panel Discussion: Choosing and Evaluating Future Commercialization Models 10:00–11:00 Cell Therapy Future Production Innovations Session Curator: Lin Youchen, WuXi AppTec MAH Production Lead Presentation: Decentralized / Bedside Manufacturing Presentation: Fast CAR-T Presentation: CMC Considerations for Global Registration	09:00-10:00 Panel Discussion: Impact of New Biomedical Technology Regulations on Gene Therapy Indication Development 10:00–11:00 Case Studies in Gene Therapy Development for Rare Diseases
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	Innovative R&D & Clinical Translation 12:00–13:00 Exosome Technology Innovation 13:00–14:00 Clinical Translation and Applications	Autoimmune Disease Drug Development 12:00–12:20 Presentation: Universal CAR-T 12:20–12:40 Presentation: Rapid Translation Strategies for Mature CAR-T Platforms 12:40–13:00 Presentation: Dual-Target CAR-T Development in Autoimmune Diseases 13:00–13:20 Presentation: Novel Therapies Using Natural Immune Cells 13:20–13:40 Presentation: Innovations in Regulatory Cell Therapy 13:40–14:00 Presentation: From Virus-Associated Tumors to Chronic Infections	Indication Development 12:00–13:00 Case Studies in Gene Therapy Development for Ophthalmic Diseases 13:00–14:40 Case Studies in Gene Therapy Development for Chronic Diseases
14:00-15:00	Networking & Events	Networking & Events	CMC and Regulatory Submission 14:40–15:00 Coordinated Development of Biomedical Technologies and Drug Submissions 15:00–16:00 Panel Discussion: CMC Development Requirements from IIT/Clinical Perspectives
15:00-18:00	Innovative R&D & Process Development 15:00–16:00 Case Studies in Innovative Development 16:00–17:00 Exosome Process Development 17:00–18:00 Scale-Up Manufacturing	Solid Tumor Drug Development 15:00–15:20 Presentation: Universal CAR-T 15:20–15:40 Presentation: Dual-Target CAR-T 15:40–16:00 Presentation: Ultra-Low Dose Metabolism-Enhanced Cell Therapy 16:00–16:20 Presentation: TCR-T Therapies 16:20–16:40 Presentation: Allogeneic TIL Therapy Based on Organoid Technology 16:40–17:00 Presentation: CAR-NK Therapies 17:00–18:00 Panel Discussion: Expanding Indications and Clinical Strategies for Cell Therapy	

BIOCHINA2026 Biomanufacturing Industry Forum

Date	March 12th	March 13th	March 14th
09:00-11:00	Exhibition Hall Closed During Opening Ceremony	Agricultural Innovation 09:00–10:00 Biostimulants, Straw Enzymatic Hydrolysis, and Synthetic Starch 10:00–11:00 Bio-Breeding, Microbial Fertilizers, and Sustainable Protein Production	Biosynthesis Technology 09:00–10:00 Enzyme Engineering and Metabolic Pathway Design 10:00–11:00 AI-Driven Design
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	Biopharmaceutical Aesthetics 12:00–13:00 Renewable Materials and Bio-Based Alternatives 13:00–14:00 Extracellular Matrix and Functional Ingredients	Biopharmaceutical Aesthetics 12:00–13:00 Renewable Materials and Bio-Based Alternatives 13:00–14:00 Extracellular Matrix and Functional Ingredients	Biological Fermentation Technology 12:00–13:00 Pilot-Scale Upscaling 13:00–14:00 Continuous-Flow Fermentation
14:00-15:00	Networking & Events	Networking & Events	Gene Editing Technology 14:00–15:00 Gene Editing 15:00–16:00 Gene Editing
15:00-18:00	Food Development 15:00–16:00 Functional Additives 16:00–17:00 Cultured Meat and Fermented Dairy Products 17:00–18:00 Synthetic Proteins	Food Development 15:00–16:00 Functional Additives 16:00–17:00 Cultured Meat and Fermented Dairy Products 17:00–18:00 Synthetic Proteins	

**BIOCHINA2026 AI Innovation
Forum**
**BIOCHINA2026 Peptide Drug
Innovation Forum**
**BIOCHINA2026 Biomanufacturing
Innovation Forum**

Date

March 13th

March 14th

 Exhibition Hall Closed During Opening
 Ceremony

Long-Acting Peptide Development

 09:00–10:20 Long-Acting Peptide Development
 10:20–11:00 Panel Discussion: Future of Long-Acting
 Peptides and Other Formulations

 Traditional Chinese Medicine
 09:00-10:00 Cutting-Edge Technologies and Innovative
 Approaches
 10:00-11:00 Biomanufacturing Development of Marine TCM and
 Special Microbial Resources

11:00-12:00

Lunch & Networking

Lunch & Networking

Lunch & Networking

12:00-14:00

AI-Powered Drug Discovery

 12:00-13:00 Target Discovery and Disease
 Mechanism Analysis Using AI
 13:00-14:00 Case Studies: AI-Driven Drug
 R&D

Clinical Development and Indication Selection

 12:00–13:00 Panel Discussion: Clinical Development and
 Peptide Acceleration Strategies
 13:00–14:00 Case Sharing: Clinical Indication
 Development for Peptide Drugs

 New Drug Development
 12:00-13:00 Cutting-Edge Technologies and Platform Building
 13:00-14:00 Future Prospects of Industrial Translation

14:00-15:00

Networking & Events

Networking & Events

15:00-18:00

AI Automated Laboratories

 15:00-16:00 Biological Automation
 Laboratory
 16:00-17:00 Chemical Automation
 Laboratory
 17:00-18:00 AI in Process Development
 and Optimization

GLP-1 Development


 15:00–16:00 Panel Discussion: Next-Generation GLP-1
 Development and Multi-Target Combinations
 16:00–17:00 Key Considerations for Enhancing GLP-1
 Safety
Process Development & Manufacturing
 17:00–18:00 Peptide Synthesis: Process Development and
 Manufacturing Essentials

 Energy
 14:00-15:00 Innovative Approaches and Emerging Technologies
 in Bioenergy
 15:00-16:00 Raw Materials, Processes, and System Integration



About the Exhibition

BIOCHINA 2026 (11th Edition) will feature six exhibition halls—**Laboratory Instruments, Pharma Equipment, Raw Materials & Reagents, Consumables, International Services**, and **General Services**. Onsite, participants can connect directly with domestic and international brands, engage with founders and senior technology executives, and enhance business cooperation efficiency between exhibitors, end users, and distribution partners.

- Laboratory Instruments Hall:** Featuring analytical instruments, low-temperature storage, and automated/intelligent lab devices.
- Pharma Equipment Hall:** Showcasing bioreactors, solution preparation, chromatography & filtration systems, and packaging equipment.
- Raw Materials & Reagents Hall:** Covering full-process raw materials and reagents, including cell culture and assay reagents, and biopharmaceutical excipients.
- Consumables Hall:** Offering cell culture and purification consumables, packaging materials, and protective equipment.
- International Service Hall – Technical Services & International Hall**
- **Technical Services:** Includes CROs, CDMOs, engineering services, logistics & cold-chain, software solutions, and science parks.
 - **International Pavilion:** Features country pavilions, overseas pharmaceutical companies, and upstream suppliers & service providers.
- General Services:** A one-stop industry hub integrating raw materials & reagents, consumables, Laboratory Instruments, Pharma Equipment, and technical services, connecting global premium brands and enterprises.



BIOCHINA Attendee Highlights



About BiOPartnering

BiOPartnering offers **1-on-1, 30-minute meetings** to discuss cutting-edge technologies, innovative applications, and industry trends. Tailored to company needs, it facilitates investment, project deals, and strategic collaborations, promoting internationalization of the biotech industry and fostering global cooperation and win-win innovation.

At BIOCHINA 2025, private meeting rooms, Exclusive Reception Room and public discussion areas hosted **1,805 companies** from **28 countries and regions**, including Biotech, Pharma, MNCs, investors, and life science service providers, resulting in **2,679 meetings**.

For BIOCHINA 2026, the platform is further enhanced with a **VIP lounge**, alongside existing meeting spaces. **Over 2,000 companies** from **40+ countries and regions** are expected, with **3,000+ meetings** anticipated.



BIOCHINA2025

Participating companies **1,805**

Meetings arranged **2,679**

Participants from **28** countries and regions

BIOCHINA2026 - Fully Upgraded

Participating companies **2,000 +**

Meetings arranged **3,000 +**

Participants from **40 +** countries and regions



About Overseas


BIOCHINA 2026 is expected to attract participants from **40+ countries and regions**, including key markets such as South Korea, Russia, the United States, India, and Singapore. Companies from **Asia, Europe, the Americas, and Oceania** will actively engage in collaborations with the Chinese market. A wide range of participation formats will be offered, including international forums, **the International Hall, 1-on-1 BiOPartnering meetings**, and **networking receptions**, providing a comprehensive platform for companies to explore new business opportunities.



Dr Reddy Inceptua Group Pfizer Inc. Canada India
Certest Pharma AbTis, Co., Ltd. Daewon Pharm. Co., Ltd.
Binnopharm Group Celltrion, Inc. Belgium Laboratorios Bago S.A.
USA Lilly Russia Torrent Pharma PROMOMED Germany
Spain 100+ senior executives from France
Novartis global pharmaceutical companies Sweden

Sun Pharma Find Projects Find Partnerships GeroPharma
GL PharmTech Daewoong Pharmaceutical Insud Pharma
Thailand Pakistan Singapore Bayer
United Kingdom Australia
Argentina Poland Korea
Pharmasyntez SENJU PHARMACEUTICAL

BIO CHINA | 2026 Fusion Forward
International Convention
融合·领先 第十一届易贸生物产业展览
March 12-14, 2026 Suzhou International Expo Center



Join us at BIOCHINA2026



▶▶▶ **BIOCHINA** ◀◀◀

Connecting Innovators, Enabling Bio-industry.
China's leading communication platform in Bio-industry



▶▶▶ **BioBD Group** ◀◀◀



▶▶▶ **BIOCHINA GCD Group** ◀◀◀
(Global Clinical Group)



▶▶▶ **WhatsApp Group** ◀◀◀